Get the Stockscreener App
5.83
3.80%
-0.23
After Hours:
5.90
0.07
+1.20%
Corvus Pharmaceuticals Inc stock is traded at $5.83, with a volume of 412.16K.
It is down -3.80% in the last 24 hours and up +29.56% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$6.06
Open:
$6.05
24h Volume:
412.16K
Relative Volume:
0.57
Market Cap:
$434.42M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-10.41
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
-5.36%
1M Performance:
+29.56%
6M Performance:
+25.92%
1Y Performance:
+13.65%
1-Day Range:
$5.82
$6.085
1-Week Range:
$5.82
$6.30
52-Week Range:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
5.83 | 441.87M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Will Corvus Pharmaceuticals Inc. price bounce be sustainableJuly 2025 WrapUp & Community Trade Idea Sharing Platform - Newser
Can machine learning forecast Corvus Pharmaceuticals Inc. recovery2025 Price Momentum & Reliable Trade Execution Plans - Newser
How to use Fibonacci retracement on Corvus Pharmaceuticals Inc.July 2025 Sentiment & Safe Entry Point Alerts - Newser
Published on: 2025-09-12 17:52:49 - Newser
Corvus Pharmaceuticals Inc. stock daily chart insightsMarket Weekly Review & AI Powered Buy/Sell Recommendations - Newser
Regression analysis insights on Corvus Pharmaceuticals Inc. performanceSell Signal & Verified Short-Term Trading Plans - Newser
Published on: 2025-09-12 13:24:02 - Newser
Multi factor analysis applied to Corvus Pharmaceuticals Inc.Earnings Recap Report & Advanced Swing Trade Entry Alerts - Newser
Will Corvus Pharmaceuticals Inc. continue its uptrendWeekly Risk Summary & AI Enhanced Trading Signals - Newser
Is a relief rally coming for Corvus Pharmaceuticals Inc. holdersJuly 2025 Institutional & Technical Buy Zone Confirmation - Newser
Using Ichimoku Cloud for Corvus Pharmaceuticals Inc. technicalsMarket Growth Report & Risk Managed Investment Entry Signals - Newser
Samlyn Capital LLC Has $12.93 Million Holdings in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Is Corvus Pharmaceuticals Inc. stock poised for growthBond Market & Reliable Price Breakout Signals - Newser
Is now a turning point for Corvus Pharmaceuticals Inc.Trade Volume Report & Consistent Profit Focused Trading Strategies - Newser
Can you recover from losses in Corvus Pharmaceuticals Inc.Trade Entry Report & Fast Exit and Entry Strategy Plans - Newser
Jump Financial LLC Makes New $143,000 Investment in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Custom strategy builders for tracking Corvus Pharmaceuticals Inc.Quarterly Trade Report & Technical Pattern Recognition Alerts - Newser
American Century Companies Inc. Acquires 45,491 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
What data driven models say about Corvus Pharmaceuticals Inc.’s futureTrade Analysis Report & AI Powered Buy/Sell Recommendations - Newser
Will Corvus Pharmaceuticals Inc. rebound enough to break even2025 Valuation Update & Fast Moving Stock Trade Plans - Newser
Using R and stats models for Corvus Pharmaceuticals Inc. forecasting2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - Newser
How to forecast Corvus Pharmaceuticals Inc. trends using time seriesPortfolio Risk Summary & Growth Focused Stock Reports - Newser
Analyzing net buyer seller activity in Corvus Pharmaceuticals Inc.July 2025 Setups & Expert Verified Stock Movement Alerts - Newser
How to monitor Corvus Pharmaceuticals Inc. with trend dashboardsQuarterly Portfolio Review & High Return Trade Guides - Newser
Will earnings trigger a reversal in Corvus Pharmaceuticals Inc.Quarterly Growth Report & Detailed Earnings Play Alerts - Newser
Analyzing recovery setups for Corvus Pharmaceuticals Inc. investorsWeekly Trading Summary & Community Driven Trade Alerts - Newser
Visual trend scoring systems applied to Corvus Pharmaceuticals Inc.Earnings Growth Summary & Daily Entry Point Trade Alerts - Newser
Analyzing Corvus Pharmaceuticals Inc. with multi timeframe chartsMarket Trend Review & Real-Time Volume Analysis Alerts - Newser
Does Corvus Pharmaceuticals Inc. outperform in volatile marketsQuarterly Market Review & AI Enhanced Trading Signals - Lancaster City Council
Pattern recognition hints at Corvus Pharmaceuticals Inc. upside2025 EndofYear Setup & Technical Confirmation Alerts - Newser
Can momentum traders help lift Corvus Pharmaceuticals Inc.Weekly Stock Analysis & AI Enhanced Market Trend Forecasts - Newser
Sentiment analysis tools applied to Corvus Pharmaceuticals Inc.2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):